Palatin Technologies announced in May 2024 that its drug, Veltassa (patiromer), received FDA approval for the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. Veltassa is an orally administered potassium binder that works by binding to potassium in the gastrointestinal tract, thereby reducing systemic absorption [1].
How is Veltassa different from other potassium binders?
Veltassa's approval marks a significant development in managing hyperkalemia, a common complication in patients with chronic kidney disease (CKD) or those taking renin-angiotensin-aldosterone system (RAAS) inhibitors. The drug's mechanism of action involves binding to potassium in the gut, preventing its absorption into the bloodstream. This offers a targeted approach to lowering elevated potassium levels, which can be critical for cardiovascular health and kidney function [1].
What are the potential benefits of Veltassa?
For patients with hyperkalemia, particularly those with CKD or on RAAS inhibitors, Veltassa provides a new therapeutic option. By effectively reducing serum potassium, it may help prevent the need to discontinue or reduce the dosage of essential RAAS inhibitor medications, which are crucial for managing conditions like heart failure and hypertension. Maintaining stable potassium levels is vital for preventing serious cardiovascular events and progression of kidney disease [1].
When does Veltassa's patent expire?
Information regarding the patent exclusivity for Veltassa can be found on specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would include Veltassa [2].
Who makes Veltassa and where is it available?
Palatin Technologies is the developer of Veltassa. Following its FDA approval, the drug is expected to become available through pharmacies for prescription use. Palatin Technologies has entered into a collaboration with Sentinel Care to commercialize Veltassa in the United States [1].
What are the risks associated with Veltassa?
As with any medication, Veltassa carries potential risks and side effects. Common side effects may include gastrointestinal issues such as diarrhea, constipation, nausea, and abdominal discomfort. Patients should consult with their healthcare provider to discuss these potential risks and determine if Veltassa is an appropriate treatment option for their specific condition [1].
How does Veltassa's availability impact generic competition?
The availability of Veltassa, a newly approved drug, means that generic versions will not be immediately available. Generic competition typically emerges after the expiration of patent protections and any associated market exclusivity periods. Until then, Veltassa will be available as a branded medication [2].
Sources:
[1] https://www.palatin.com/
[2] https://drugpatentwatch.com/